Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16:2022:6426800.
doi: 10.1155/2022/6426800. eCollection 2022.

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

Yue Han  1 , Jing Chen  2 , Dianjun Wei  3 , Baoxi Wang  3
Affiliations

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

Yue Han et al. Comput Math Methods Med. .

Retraction in

Abstract

Objective: To assess KIF11 expression in human thyroid tumor tissues and further evaluate its involvement in thyroid cancer.

Methods: The expression of KIF11 in 71 cases of thyroid carcinoma as well as corresponding tissues was detected by the immunohistochemical (IHC) method. Patients were divided into the high KIF11 expression as well as low expression groups based on the staining levels. In addition, to study the relationship between the expression of KIF11 as well as clinicopathological features, the effects of KIF11 were detected on the proliferation, apoptosis, and cell cycle of two types of thyroid cancer cells, TPC-1 and KTC-1, through colony formation assays, MTT assays, and FCM assays, respectively. We further assessed the potential effects of KIF11 on tumor growth using an animal model.

Results: The significantly high expression of KIF11 in thyroid tumor tissues was revealed, and the correlations between KIF11 expression levels as well as clinical pathological features (T stage and intraglandular dissemination) of patients were revealed. We further noticed that KIF11 knockdown remarkably suppressed thyroid cancer cell proliferation as well as induced cell apoptosis of thyroid cancer cells. Additionally, KIF11 contributed to tumor growth of thyroid cancer cells in mice.

Conclusions: We noticed the involvement of KIF11 in the progression of thyroid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
KIF11 expression in different types of cancer tissues according to TCGA database.
Figure 2
Figure 2
KIF11 expression in tumor tissues and normal tissues according to the GEPIA database.
Figure 3
Figure 3
KIF11 was highly expressed in human thyroid tumor tissues. (a) The representative photographs of IHC assays showed the expression of KIF11 in thyroid cancer tissues (100x and 200x magnification, respectively). (b) IHC assays were performed to exhibit KIF11 expression levels in adjacent tissues, and the representative photographs are shown (100x and 200x magnification, respectively). Scale bar, 50 μm.
Figure 4
Figure 4
The expression levels of KIF11 were effectively decreased in both TPC-1 and KTC-1 cells caused by the transfection of KIF11 shRNA plasmids. (a) The results of quantitative PCR assays showed the obviously decreased expression levels of KIF11 caused by the transfection of its shRNA plasmids in TPC-1 and KTC-1 cells, respectively. (b) Immunoblot assays showed KIF11 expression levels upon the transfection of control or KIF11 shRNA plasmids in both TPC-1 and KTC-1 cells. Results are presented as the mean ± SD, ∗p < 0.05.
Figure 5
Figure 5
KIF11 fascinates thyroid cancer cell proliferation and suppresses cell apoptosis in vitro. (a) Colony formation assays were conducted using TPC-1 and KTC-1 cell transfection, and the number of colonies was counted. Scale bar, 5 mm. (b) MTT assays showed the OD value at 570 nm wavelength of KIF11-depleted cells. (c) FCM assays confirmed the effects of KIF11 depletion on the apoptosis in TPC-1 and KTC-1 cells. (d) FCM assays showed that KIF11 ablation led to the arrest of cell cycle in TPC-1 and KTC-1 cells. Results are presented as the mean ± SD, ∗p < 0.05.
Figure 6
Figure 6
KIF11 promotes tumor growth of thyroid cancer in mice. (a) Tumor growth curves were shown. Scale bar, 5 mm. (b) Immunoblot assays exhibited the expression levels of KIF11 in tumors isolated from mice. Results are presented as the mean ± SD, ∗p < 0.05.
See this image and copyright information in PMC

References

    1. Milano A. F. Thyroid cancer: 20-year comparative mortality and survival analysis of six thyroid cancer histologic subtypes by age, sex, race, stage, cohort entry time-period and disease duration (SEER∗ Stat 8.3. 2) a systematic review of 145,457 cases for diagnosis years 1993–2013. Journal of Insurance Medicine . 2018;47(3):143–158. doi: 10.17849/insm-47-03-143-158.1. - DOI - PubMed
    1. Ellis M., Cohen K., Maman E. S., Hercbergs A., Davis P. J., Ashur-Fabian O. The involvement of thyroid hormones in cancer. Harefuah . 2015;154(8):512–515. - PubMed
    1. Pitoia F., Bueno F., Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131iodine-avid lung metastasis from differentiated thyroid cancer. Clinical Nuclear Medicine . 2014;39(9):784–790. doi: 10.1097/RLU.0000000000000507. - DOI - PubMed
    1. Alvarado R., Sywak M. S., Delbridge L., Sidhu S. B. Central lymph node dissection as a secondary procedure for papillary thyroid cancer: is there added morbidity? Surgery . 2009;145(5):514–518. doi: 10.1016/j.surg.2009.01.013. - DOI - PubMed
    1. Faulkner S., Roselli S., Demont Y., et al. ProNGF is a potential diagnostic biomarker for thyroid cancer. Oncotarget . 2016;7(19):28488–28497. doi: 10.18632/oncotarget.8652. PMID: 27074571. - DOI - PMC - PubMed

Publication types